Abstract 3650: <i>In Vitro and in vivo synergistic anticancer effect of HDAC inhibitor panobinostat (LBH589) plus zoledronic acid in human prostate, breast and multiple myeloma tumor models</i>

Monia Rocco(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alfredo Budillon(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Claudio Arra(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Antonio Luciano(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Biagio Pucci(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Maria Chianese(University of Trieste), Elena Di Gennaro(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Maria Rita Milone(Centro di Riferimento Oncologico), Francesca Bruzzese(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Sabrina Rosano(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cancer Research
April 1, 2010
10.1158/1538-7445.am10-3650
Cited by 0

Related Papers

Emerging anti-cancer molecular mechanisms of aminobisphosphonates
|Endocrine Related Cancer|2006|131
Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation
|Journal of Experimental & Clinical Cancer Research|2019|125
Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows
|Pharmaceuticals|2024|86
Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells
|Cell Death and Disease|2013|63
Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways
|Cell Death and Disease|2013|57